FDA Decision on Heron's Non-Opioid Pain Med Imminent
We think Heron (HRTX) has a very good chance of approval by the FDA by the April 30, 2019 due date for its non-opioid pain med HTX-011....
${alertText}
Want unlimited access? Try Pro free for 7 days.
FDA Decision on Heron's Non-Opioid Pain Med Imminent
Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle
Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle
SGMO Shows Early Progress in Gene Therapy and Ex-Vivo Programs
Big/Suspected Movers FAQ/User Guide
Quarterly Big Mover Biotech Stocks To Watch
Q2 2023 Product Revenue Analyses
BPIQ Q2 2023 Biotech Hedge Fund (13F) Analysis
SYFOVRE (APLS) vs. IZERVAY (Astellas)
BIIB & SAGE: Zuranolone
Apellis Pharmaceuticals (APLS)
Our platform helps you uncover your next biotech investment opportunity